Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hero Technologies Inc. stock logo
HENC
Hero Technologies
$0.00
$0.00
$0.00
$0.01
$50K1.35101,000 shs100,000 shs
NEPTF
Neptune Wellness Solutions
$0.03
$0.02
$0.00
$0.12
$136K-2.627,709 shs2 shs
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
$0.00
$0.02
$0.00
$1.69
$166K0.57215,590 shsN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.04
+20.5%
$0.04
$0.03
$15.67
$209K1.7520,380 shs88,536 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hero Technologies Inc. stock logo
HENC
Hero Technologies
0.00%0.00%0.00%0.00%0.00%
NEPTF
Neptune Wellness Solutions
0.00%0.00%0.00%+498.00%+2,989,900.00%
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
0.00%0.00%0.00%-97.60%-99.78%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
+3.68%-9.38%-13.33%-37.41%-99.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hero Technologies Inc. stock logo
HENC
Hero Technologies
$0.00
$0.00
$0.00
$0.01
$50K1.35101,000 shs100,000 shs
NEPTF
Neptune Wellness Solutions
$0.03
$0.02
$0.00
$0.12
$136K-2.627,709 shs2 shs
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
$0.00
$0.02
$0.00
$1.69
$166K0.57215,590 shsN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.04
+20.5%
$0.04
$0.03
$15.67
$209K1.7520,380 shs88,536 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hero Technologies Inc. stock logo
HENC
Hero Technologies
0.00%0.00%0.00%0.00%0.00%
NEPTF
Neptune Wellness Solutions
0.00%0.00%0.00%+498.00%+2,989,900.00%
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
0.00%0.00%0.00%-97.60%-99.78%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
+3.68%-9.38%-13.33%-37.41%-99.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hero Technologies Inc. stock logo
HENC
Hero Technologies
0.00
N/AN/AN/A
NEPTF
Neptune Wellness Solutions
2.00
HoldN/AN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
2.50
Moderate Buy$4.00133,233.33% Upside
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
3.00
Buy$40.0099,900.00% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hero Technologies Inc. stock logo
HENC
Hero Technologies
N/AN/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
$3.09M0.05N/AN/A$1.05 per share0.00
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hero Technologies Inc. stock logo
HENC
Hero Technologies
-$540KN/A0.00N/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/AN/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
-$97.43M-$1.33N/AN/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hero Technologies Inc. stock logo
HENC
Hero Technologies
N/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hero Technologies Inc. stock logo
HENC
Hero Technologies
N/AN/AN/A
NEPTF
Neptune Wellness Solutions
N/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17

Institutional Ownership

CompanyInstitutional Ownership
Hero Technologies Inc. stock logo
HENC
Hero Technologies
N/A
NEPTF
Neptune Wellness Solutions
11.72%
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
97.47%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%

Insider Ownership

CompanyInsider Ownership
Hero Technologies Inc. stock logo
HENC
Hero Technologies
0.21%
NEPTF
Neptune Wellness Solutions
5.10%
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
8.50%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hero Technologies Inc. stock logo
HENC
Hero Technologies
1456.69 million455.73 millionNot Optionable
NEPTF
Neptune Wellness Solutions
1304.53 million4.30 millionN/A
Omega Therapeutics, Inc. stock logo
OMGAQ
Omega Therapeutics
12055.37 million50.66 millionOptionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable

Recent News About These Companies

Vincerx Pharma, Inc. (VINC) - Yahoo Finance
Vincerx Pharma announces plan to delist from Nasdaq
Vincerx Pharma announces non-binding LOI for Qumulus AI combination

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hero Technologies stock logo

Hero Technologies OTCMKTS:HENC

$0.0001 0.00 (0.00%)
As of 01:03 PM Eastern

Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.

Neptune Wellness Solutions OTC:NEPTF

$0.03 0.00 (0.00%)
As of 09/16/2025

Neptune Wellness Solutions Inc. operates as an integrated health and wellness company. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga Neutraceuticals, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, and NurturMe brands. The company offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, such as legal cannabis and hemp, nutraceuticals, and white label consumer packaged goods. It is also involved in the extraction, purification, formulation, and manufacturing of health and wellness products, such as omega-3 and hemp-derived products under various delivery forms, such as soft gels, liquids, capsules, vape pens, sprays, topicals, sachets, tinctures, concentrates, edibles, and beverages, as well as hand sanitizers, non-contact thermometers, and gloves. In addition, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.

Omega Therapeutics stock logo

Omega Therapeutics OTCMKTS:OMGAQ

$0.0030 0.00 (0.00%)
As of 08/11/2025

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.04 +0.01 (+20.48%)
As of 03:12 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.